Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs

Blood. 2007 Apr 15;109(8):3609-10. doi: 10.1182/blood-2006-11-058032.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / agonists
  • Antineoplastic Agents / pharmacokinetics*
  • Antineoplastic Agents / pharmacology
  • Apoptosis / drug effects
  • Benzamides
  • Cell Line
  • Drug Synergism
  • Drug Therapy, Combination
  • Fusion Proteins, bcr-abl / genetics
  • Fusion Proteins, bcr-abl / metabolism
  • Humans
  • Imatinib Mesylate
  • Leukemia / drug therapy*
  • Leukemia / genetics
  • Leukemia / metabolism*
  • Leukemia / pathology
  • Male
  • Mice
  • Models, Biological
  • Phosphotyrosine / metabolism
  • Piperazines / agonists
  • Piperazines / pharmacokinetics*
  • Piperazines / pharmacology
  • Pyrimidines / agonists
  • Pyrimidines / pharmacokinetics*
  • Pyrimidines / pharmacology
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Phosphotyrosine
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • nilotinib